JPWO2020138370A1 - Ｃｄｋ阻害剤を含有する癌治療用医薬組成物 - Google Patents

Ｃｄｋ阻害剤を含有する癌治療用医薬組成物 Download PDF

Info

Publication number
JPWO2020138370A1
JPWO2020138370A1 JP2020562462A JP2020562462A JPWO2020138370A1 JP WO2020138370 A1 JPWO2020138370 A1 JP WO2020138370A1 JP 2020562462 A JP2020562462 A JP 2020562462A JP 2020562462 A JP2020562462 A JP 2020562462A JP WO2020138370 A1 JPWO2020138370 A1 JP WO2020138370A1
Authority
JP
Japan
Prior art keywords
cancer
androgen receptor
composition according
phosphorylation
androgen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020562462A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020138370A5 (https=
Inventor
英二郎 中村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of JPWO2020138370A1 publication Critical patent/JPWO2020138370A1/ja
Publication of JPWO2020138370A5 publication Critical patent/JPWO2020138370A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020562462A 2018-12-27 2019-12-26 Ｃｄｋ阻害剤を含有する癌治療用医薬組成物 Pending JPWO2020138370A1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018244174 2018-12-27
JP2018244174 2018-12-27
PCT/JP2019/051310 WO2020138370A1 (ja) 2018-12-27 2019-12-26 Ｃｄｋ阻害剤を含有する癌治療用医薬組成物

Publications (2)

Publication Number Publication Date
JPWO2020138370A1 true JPWO2020138370A1 (ja) 2021-11-11
JPWO2020138370A5 JPWO2020138370A5 (https=) 2022-11-09

Family

ID=71126081

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020562462A Pending JPWO2020138370A1 (ja) 2018-12-27 2019-12-26 Ｃｄｋ阻害剤を含有する癌治療用医薬組成物

Country Status (3)

Country Link
US (1) US20220071978A1 (https=)
JP (1) JPWO2020138370A1 (https=)
WO (1) WO2020138370A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017534248A (ja) * 2014-08-25 2017-11-24 ザ ジョンズ ホプキンズ ユニヴァーシティー 前立腺がん治療に関する方法及び組成物
JP2018177658A (ja) * 2017-04-05 2018-11-15 公立大学法人名古屋市立大学 去勢抵抗性前立腺癌の治療

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017534248A (ja) * 2014-08-25 2017-11-24 ザ ジョンズ ホプキンズ ユニヴァーシティー 前立腺がん治療に関する方法及び組成物
JP2018177658A (ja) * 2017-04-05 2018-11-15 公立大学法人名古屋市立大学 去勢抵抗性前立腺癌の治療

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GORDON V.ET AL.: "CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation", MOL.ENDCRINOL., vol. 24, JPN6020003152, 2010, pages 2267 - 2280, ISSN: 0005243237 *

Also Published As

Publication number Publication date
US20220071978A1 (en) 2022-03-10
WO2020138370A1 (ja) 2020-07-02

Similar Documents

Publication Publication Date Title
JPWO2020138370A1 (ja) Ｃｄｋ阻害剤を含有する癌治療用医薬組成物
EP3760623B1 (en) Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
RS66557B1 (sr) [1,3]diazino[5,4-d]pirimidini kao her2 inhibitori
JP2023182572A (ja) がんの診断及び治療方法
WO2020190765A2 (en) Compositions and methods for treating cancer
US20250367287A1 (en) Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor
JP2021506973A (ja) がん治療のための１−（ピペリジノカルボニルメチル）−２−オキソピペラジン誘導体
KR20170083997A (ko) 암 줄기세포 치료용 조성물
TW202543645A (zh) 抗癌組合治療
CN118159534A (zh) 抑制PI3K同工型α的化合物和用于治疗癌症的方法
KR20210100604A (ko) 암의 치료 및/또는 예방용 우레아 유도체
US20240408100A1 (en) Treatment methods for subjects having cancer with a dysregulated mapk and/or pi3k pathway
WO2024254298A1 (en) A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
EP4724150A1 (en) A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer
JP7254020B2 (ja) 融合遺伝子を含有するがんを治療する方法
Howard Characterization of the CXCR4-LASP1-eIF4F Axis in Triple-Negative Breast Cancer
WO2017189647A1 (en) Methods and compositions for the treatment of myelodysplastic syndrome
WORK THE ACTIVITY OF DNA-PK INHIBITORS IN SCLC WITH HIGH C-MYC EXPRESSION
BR112024002063B1 (pt) Compostos que inibem isoforma alfa de pi3k, composições que o compreendem, usos dos mesmos, e combinações
HK40028536A (en) Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
Dao-Hong et al. Targeted therapy: resistance and re-sensitization
BR122025018069A2 (pt) Método para o diagnóstico de um indivíduo com um tumor her2 positivo como sendo resistente ou susceptível ao tratamento com trastuzumab-mcc-dm1 e kit para o diagnóstico ou prognóstico in vitro de um tumor her2 positivo resistente ao tratamento com trastuzumab-mcc-dm1 em uma amostra biológica
JP2017214367A (ja) 悪性リンパ腫の処置用の医薬組成物
HK1195737B (en) Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use
HK1195737A (zh) Akt抑制劑化合物和化療劑的組合以及使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221031

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221031

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230728

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231031

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240123